Physician profile
Stephan R Izzi
NPI 1629079173
$14,439.56
in general payments reported to CMS, 2019-2025
55 companies · $1,962 in 2025
The $1,962 reported for 2025 was more than what 95% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,917 · 2020: $1,710 · 2021: $2,626 · 2022: $1,858 · 2023: $1,947 · 2024: $2,419 · 2025: $1,962.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,325 · Education: $2.26.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,325.30 |
| Education | $2.26 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $1,876.38 | 2019-2025 | Rybelsus, Ozempic, Wegovy |
| Astrazeneca Pharmaceuticals LP | $1,667.87 | 2019-2025 | Airsupra, Breztri, Farxiga |
| Abbvie INC. | $1,569.03 | 2021-2025 | |
| Allergan, INC. | $723.87 | 2019-2021 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $693.71 | 2021-2025 | Caplyta |
| Pfizer INC. | $676.36 | 2019-2025 | |
| Lilly USA, LLC | $628.45 | 2019-2025 | Mounjaro, Zepbound, Trulicity |
| Bayer Healthcare Pharmaceuticals INC. | $579.32 | 2021-2025 | |
| Janssen Pharmaceuticals, INC | $568.68 | 2019-2024 | Xarelto |
| Glaxosmithkline, LLC. | $512.58 | 2020-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Boehringer Ingelheim Pharmaceuticals, INC. | $510.77 | 2019-2025 | Jardiance |
| Merck Sharp & Dohme LLC | $475.43 | 2020-2025 | Verquvo, Gardasil 9, Belsomra |
| Astellas Pharma US INC | $314.64 | 2021-2025 | Veozah |
| Exact Sciences Corporation | $292.68 | 2023-2025 | The Cologuard Plus Collection Kit, Cologuard Collection Kit |
| Otsuka America Pharmaceutical, INC. | $244.32 | 2019-2025 | Rexulti, Abilify Maintena, Abilify Asimtufii |
Show all 55 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Stephan Izzi listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.